Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer
RESEARCH TRIANGLE PARK, NC – April 14, 2015 – Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company’s NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.